Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
941 to 960 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing. | Front Immunol | 2022 | 36569868 | PubTator, text mining | PubMed |
| Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. | Front Immunol | 2022 | 36569859 | PubTator, text mining | PubMed |
| Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. | Cells | 2022 | 36552849 | PubTator, text mining | PubMed |
| Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare? | Cells | 2022 | 36552738 | PubTator, text mining | PubMed |
| Harnessing the Power of Mucosal-Associated Invariant T (MAIT) Cells in Cancer Cell Therapy. | Biomedicines | 2022 | 36551916 | PubTator, text mining | PubMed |
| The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions. | Cancers (Basel) | 2022 | 36551661 | PubTator, text mining | PubMed |
| Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? | Cancers (Basel) | 2022 | 36551511 | PubTator, text mining | PubMed |
| Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma. | Cancers (Basel) | 2022 | 36551506 | PubTator, text mining | PubMed |
| Chimeric antigen receptor T-cell therapy for T-ALL and AML. | Front Oncol | 2022 | 36523990 | PubTator, text mining | PubMed |
| Optimization of Culture Media for Ex vivo T-Cell Expansion for Adoptive T-Cell Therapy. | Adv Biomed Res | 2022 | 36518860 | PubTator, text mining | PubMed |
| Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa. | Antib Ther | 2022 | 36518225 | PubTator, text mining | PubMed |
| Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). | J Transl Med | 2022 | 36517851 | PubTator, text mining | PubMed |
| Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? | Best Pract Res Clin Haematol | 2022 | 36517124 | PubTator, text mining | PubMed |
| Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. | Cancer Cell | 2022 | 36513049 | PubTator, text mining | PubMed |
| Targeting macrophages: a novel treatment strategy in solid tumors. | J Transl Med | 2022 | 36510315 | PubTator, text mining | PubMed |
| Innovation in BCMA CAR-T therapy: Building beyond the Model T. | Front Oncol | 2022 | 36505779 | PubTator, text mining | PubMed |
| Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions. | Front Immunol | 2022 | 36505428 | PubTator, text mining | PubMed |
| Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. | Radiol Oncol | 2022 | 36503716 | PubTator, text mining | PubMed |
| Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. | Int J Mol Sci | 2022 | 36499331 | PubTator, text mining | PubMed |
| IL-1RAP, a Key Therapeutic Target in Cancer. | Int J Mol Sci | 2022 | 36499246 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=48